Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 54,948 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Patient Clear all
Terminated Phase 1 Interventional

Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer

NCT02559024
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
MEDI6469
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Nov 9, 2026, 1:09 AM EST
Active, not recruiting Phase 1 Interventional

Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia

NCT03983824
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Cytarabine, Echocardiography Test, Etoposide Phosphate, Mitoxantrone Hydrochloride, Multigated Acquisition Scan, Peposertib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
15
States / cities
Duarte, California • Los Angeles, California • Newport Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Nov 9, 2026, 1:09 AM EST
Active, not recruiting Phase 1 Interventional

Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery

NCT01947023
View directory record Official record
Conditions
Metastatic Thyroid Gland Carcinoma, Unresectable Thyroid Gland Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Dabrafenib, Dabrafenib Mesylate, Echocardiography Test, Lapatinib, Lapatinib Ditosylate, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Nov 9, 2026, 1:09 AM EST
Completed Not applicable Interventional

A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)

NCT01542866
View directory record Official record
Conditions
Age Related Macular Degeneration (AMD)
Interventions
Health Management Tool (HMT)
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
23
States / cities
Beverly Hills, California • Sacramento, California • Torrance, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Nov 9, 2026, 1:09 AM EST
Completed Phase 2 Interventional

A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive Patients

NCT00002322
View directory record Official record
Conditions
HIV Infections
Interventions
Atevirdine mesylate, Zidovudine
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
12
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 9, 2026, 1:09 AM EST
Completed No phase listed Observational

Screening and Evaluation of Patients With Signs and Symptoms of Alzheimer's Disease

NCT00955422
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
45 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Nov 9, 2026, 1:09 AM EST
Active, not recruiting Phase 2 Interventional

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

NCT06190951
View directory record Official record
Conditions
Melanoma
Interventions
cemiplimab, Fixed Dose Combination (FDC) cemiplimab+fianlimab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
28
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Nov 9, 2026, 1:09 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Role of p53 Gene in Metabolism Regulation in Patients With Li-Fraumeni Syndrome

NCT00406445
View directory record Official record
Conditions
Mitochondrial Disorders, Li-Fraumeni Syndrome, Carriers of p53 Mutation
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Nov 9, 2026, 1:09 AM EST
Not listed Not applicable Interventional

The ROle of Compression StocKings in Heart Failure Patients

NCT06350695
View directory record Official record
Conditions
Heart Failure，Congestive, Leg Edema, Venous Insufficiency, Venous Ulcers
Interventions
low grade compression stockings (10-15 mmHg), high grade compression stockings (20-30 mmHg)
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Nov 9, 2026, 1:09 AM EST
Withdrawn Phase 2 Interventional

Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer

NCT03836157
View directory record Official record
Conditions
Endometrial Cancer, Endometrial Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma
Interventions
Mirvetuximab Soravtansine, Bevacizumab
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Nov 9, 2026, 1:09 AM EST
Not listed Phase 3 Interventional

Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer

NCT00021281
View directory record Official record
Conditions
Colorectal Cancer
Interventions
FOLFIRI regimen, fluorouracil, irinotecan hydrochloride, leucovorin calcium, semaxanib
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Nov 9, 2026, 1:09 AM EST
Completed Phase 4 Interventional Results available

Study of Sedative Medications in Patients With Severe Infection and Respiratory Failure

NCT02203019
View directory record Official record
Conditions
Sepsis, Respiratory Failure, Agitation
Interventions
Propofol, Dexmedetomidine, Fentanyl
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 89 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Nov 9, 2026, 1:09 AM EST
Completed Phase 2 Interventional Results available

The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer

NCT00215930
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Vinorelbine, Docetaxel, Gemcitabine, Carboplatin
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Nov 9, 2026, 1:09 AM EST
Completed Not applicable Interventional

Rehabilitation of Patients With COPD Using Electrical Muscle Stimulation

NCT01799330
View directory record Official record
Conditions
COPD
Interventions
Transcutaneous Electrical Muscle Stimulation (TCEMS), Sham TCEMS
Procedure · Other
Lead sponsor
Yale University
Other
Eligibility
Up to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Nov 9, 2026, 1:09 AM EST
Recruiting No phase listed Observational

Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)

NCT06098430
View directory record Official record
Conditions
Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
8 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
7
States / cities
Palo Alto, California • Aurora, Colorado • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Nov 9, 2026, 1:09 AM EST
Active, not recruiting Phase 2 Interventional

Safety, PK and PD Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

NCT06175065
View directory record Official record
Conditions
Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Interventions
RLS-0071, Placebo
Drug
Lead sponsor
ReAlta Life Sciences, Inc.
Industry
Eligibility
30 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
St. Petersburg, Florida • Glen Burnie, Maryland • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Nov 9, 2026, 1:09 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance

NCT03114865
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma, Pre B-Cell Acute Lymphoblastic Leukaemia
Interventions
Blinatumomab 9ug, Blinatumomab 28 ug, Blinatumomab, Dexamethasone
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 9, 2026, 1:09 AM EST
Active, not recruiting Not applicable Interventional

Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function

NCT04763200
View directory record Official record
Conditions
Left Ventricular Dysfunction, Coronary Artery Disease
Interventions
Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump
Device
Lead sponsor
Abiomed Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
1,252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
83
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Nov 9, 2026, 1:09 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cesarean Trial of Staples vs. Sutures

NCT01211600
View directory record Official record
Conditions
Cesarean Section, Wound Complications, Patient Satisfaction, Pain Measurement
Interventions
Staples, Suture
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
Female only
Enrollment
746 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
2
States / cities
New Haven, Connecticut • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Nov 9, 2026, 1:09 AM EST
Recruiting Early Phase 1 Interventional

Implantable Microdevice In Primary Brain Tumors

NCT04135807
View directory record Official record
Conditions
Grade II Glioma, Grade III Glioma, Grade IV Glioma, Astrocytoma, Oligodendroglioma of Brain, Anaplastic Astrocytoma of Brain, Anaplastic Oligodendroglioma, Glioblastoma
Interventions
Microdevice
Combination Product
Lead sponsor
Oliver Jonas
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 9, 2026, 1:09 AM EST
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Losartan on Airway Mucociliary Dysfunction in Patients With COPD and Chronic Bronchitis

NCT02416102
View directory record Official record
Conditions
COPD, Chronic Bronchitis
Interventions
Losartan 50 mg, Losartan 100 mg
Drug
Lead sponsor
University of Miami
Other
Eligibility
35 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Nov 9, 2026, 1:09 AM EST
Completed Phase 2 Interventional Results available

Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors

NCT04525131
View directory record Official record
Conditions
Bladder Cancer
Interventions
CPX-POM
Drug
Lead sponsor
CicloMed LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2024 · Synced Nov 9, 2026, 1:09 AM EST
Not listed No phase listed Observational

Immunologic Evaluation in Patients With DiGeorge Syndrome or Velocardiofacial Syndrome

NCT00005102
View directory record Official record
Conditions
DiGeorge Syndrome, Shprintzen Syndrome, Chromosome Abnormalities, Abnormalities, Multiple, Conotruncal Cardiac Defects
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 9, 2026, 1:09 AM EST
Terminated Phase 2 Interventional Results available

Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer

NCT00003453
View directory record Official record
Conditions
Stage IV Adrenocortical Carcinoma
Interventions
Antineoplaston therapy (Atengenal + Astugenal)
Drug
Lead sponsor
Burzynski Research Institute
Other
Eligibility
6 Months to 99 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Nov 9, 2026, 1:09 AM EST